Tuesday 15 September 2026
Evening EditionRSS

ZOTPAPER

News without the noise

ZOTPAPER
Australia

Rise of 'egg timer' fertility tests prompts warnings from doctors

Experts say anti-Müllerian hormone tests cannot predict conception likelihood

edit
By LineZotpaper
Published
Read Time2 min
Sources3 outlets
More Australian women are seeking out the so-called 'egg timer' fertility test, but doctors warn the anti-Müllerian hormone (AMH) test is being marketed misleadingly and cannot determine a woman's actual chances of conceiving.

An increasing number of women are opting for the 'egg timer' test, a blood test that measures anti-Müllerian hormone (AMH) levels, often marketed as a way to gauge ovarian reserve and fertility potential. However, medical experts are raising concerns that the test is being oversold and misinterpreted, leading to unnecessary anxiety or false reassurance.

The test, which became popular through direct-to-consumer marketing and private fertility clinics, measures the quantity of eggs remaining in a woman's ovaries, but does not assess egg quality or the likelihood of natural conception. Dr Sarah Johnson, a reproductive endocrinologist, explained: 'AMH levels can vary widely and fluctuate with age, oral contraceptive use, and other factors. It's not a crystal ball for fertility.'

The Australian Medical Association has called for clearer regulation of fertility testing, urging women not to base life-changing decisions on AMH results alone. Many women pay hundreds of dollars for the test out of pocket, only to receive results that may not reflect their true fertility status.

Supporters of the test argue it can help women plan their reproductive timelines, especially those considering egg freezing. But critics contend that without a full fertility workup and understanding of individual health, AMH testing can be misleading. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists has advised that AMH testing should only be used in specific clinical contexts, such as prior to IVF or cancer treatment.

The trend has been fueled by social media influencers and wellness brands promoting the test as a proactive health measure. Yet doctors warn that for most women under 35, the test provides no useful information about current fertility. 'A low AMH does not mean you can't get pregnant now, and a high AMH does not guarantee you will,' said Dr Johnson.

As the debate continues, health authorities urge women to consult with their GP or a fertility specialist before undergoing the test, and to treat any results with caution.

§

Analysis

Why This Matters

  • Misleading marketing can lead women to make poor reproductive decisions based on unreliable data.
  • Financial costs — women pay out of pocket for tests with limited clinical value.
  • Policy gap — current regulation allows the test to be sold as a fertility predictor without strong evidence.

Background

The anti-Müllerian hormone test was originally developed to assess ovarian reserve in IVF patients and women undergoing cancer treatment. In the past decade, it has been repackaged as a consumer fertility test, often called the 'egg timer' due to its implied ability to count down remaining fertile years. Medical guidelines have consistently warned against using AMH alone to predict natural conception, but direct-to-consumer marketing has outpaced regulatory oversight. The trend has grown rapidly on social media, where influencers promote the test as a tool for 'taking control' of fertility.

Key Perspectives

Fertility specialists: Stress that AMH only measures egg quantity, not quality, and cannot predict time to pregnancy. They urge women not to make life decisions based on the test alone. Private clinics and test providers: Argue that the test provides valuable information about ovarian reserve, empowering women to make informed choices about family planning and egg freezing. Critics/Skeptics: Warn that the test creates unnecessary stress for women with low AMH and false security for those with high AMH. They point to studies showing many women with 'low' AMH conceive naturally without issues.

What to Watch

  • Regulatory response — will the TGA or AMA issue new guidelines about direct-to-consumer fertility testing?
  • Research — upcoming studies may clarify the clinical utility of AMH in healthy women.
  • Social media content — how influencers and wellness brands continue to promote the test will shape public perception.

Sources

newspaper

Zotpaper

Articles published under the Zotpaper byline are synthesized from multiple source publications by our AI editor and reviewed by our editorial process. Each story combines reporting from credible outlets to give readers a balanced, comprehensive view.

Editorial ProcessSubscribe